Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 25, 2023 / 03:30PM GMT
Release Date Price: $48.85 (+1.66%)
Brad Canino
Stifel Financial Corp. - Analyst

Hey. I'm Brad Canino, senior analyst here at Stifel. Thanks again for joining us on our first day of the targeted oncology days we're hosting here across several of my analyst colleagues. Happy to continue the fireside chat sessions here with Blueprint. I'm really delighted to have Percy Carter, Chief Scientific Officer; Fouad Namouni, the President, Research & Development. Thank you both for joining us today.

Fouad Namouni
Blueprint Medicines Corporation - President, Research & Development

Thank you, Brad. Happy to be here.

Questions & Answers

Brad Canino
Stifel Financial Corp. - Analyst

I think we're going to keep this conversation pretty asset focused in line with the theme of the event as well. No, questions on ISM, but I'm sure there's a lot of transcripts even from some Stifel conferences recently that cover a lot of those questions. So, on the oncology franchise, I'll start with BLU-945 for frontline EGFR-mutant non-small cell lung cancer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot